The purpose of this research study is to learn whether the combination of daratumumab SC (
Darzalex Faspro), lenalidomide (Revlimid), bortezomib (Velcade) and dexamethasone works in
treating smoldering multiple myeloma and preventing progression to active or symptomatic
multiple myeloma.
The names of the study drugs involved in this study are:
- Daratumumab (also called Darzalex Faspro)
- Bortezomib (also called Velcade)
- Lenalidomide (also called Revlimid)
- Dexamethasone